 |
26 Diseases |  |
58 Trials |
|
58 Trials |  |
4692 News |  |
| «12...2021222324252627282930...6263» |
- Cost versus price of key drugs to treat COVID-19, HIV, HBV and HCV () - May 12, 2022 - Abstract #AIDS2022AIDS_2061;
Key viral infections can be treated or cured with generic drugs at prices far below those of branded equivalents.Use of branded drugs at high prices can limit the potential for countries to achieve the UNAIDS 95-95-95 targets.
- Tivicay (dolutegravir) / ViiV Healthcare
Effectsof multi month dispensing on viral suppression and continuity in treatment among HIV-infected children aged 2 to 9 years in selected health facilities in Western Kenya () - May 12, 2022 - Abstract #AIDS2022AIDS_1987;
MMD for CLHIV may contribute towards the improvement of VS and continuity in treatment. Continued MMD implementation beyond the COVID-19 pandemic may be beneficial in improving treatment outcomes.
- Tivicay (dolutegravir) / ViiV Healthcare
Viral suppression levels among newly enrolled ART patients on multi-month dispensing of antiretroviral drugs () - May 12, 2022 - Abstract #AIDS2022AIDS_1983;
Approximately two thirds of newly enrolled patients achieved VL suppression after 6 months and 12 months on ART. Multi-month ART dispensing is a plausible option for newly enrolled ART patients.
- Tivicay (dolutegravir) / ViiV Healthcare
Multi-month dispensing and use of dolutegravir associated with better viral suppression among children in Nigeria () - May 12, 2022 - Abstract #AIDS2022AIDS_1981;
Slightly over half of the children achieved undetectable VL levels. VL suppression is higher among children on MMD and those on DTG, and even higher among children on DTG plus MMD.
- Tivicay (dolutegravir) / ViiV Healthcare
A 'One Stop' Differentiated Service Delivery Model in the Maternal and Child Health Clinics improves compliance and viral suppression among children, pregnant and breastfeeding women in Lusaka District, Zambia () - May 12, 2022 - Abstract #AIDS2022AIDS_1980;
The one-stop DSD model has resulted in improvements in prevention, linkages to care, treatment, and ART adherence for mothers and children under the age of 5 years. This model has implication for prevention of mother to child transmission of HIV (PMTCT), increased care coordination and viral suppression for the mothers and children.
- Tivicay (dolutegravir) / ViiV Healthcare
Task-shifting for viral suppression: piloting a provider-peer case management approach to support unsuppressed people living with HIV (PLHIV) at Wantanshi Health Center (CS) in the Democratic Republic of Congo (DRC) () - May 12, 2022 - Abstract #AIDS2022AIDS_1772;
Our results highlight the feasibility of using this collaborative case management system to improve viral suppression outcomes for unsuppressed PLHIV at Wantanshi CS. Scaling up collaborative approaches to support PLHIV is critical to maximizing use of existing resources to help people achieve optimal health outcomes and reach viral suppression targets.
- Tivicay (dolutegravir) / ViiV Healthcare
Factors associated with viral non-suppression among HIV positive children and adolescents enrolled to the orphans and vulnerable program in Uganda () - May 12, 2022 - Abstract #AIDS2022AIDS_1761;
Scaling up collaborative approaches to support PLHIV is critical to maximizing use of existing resources to help people achieve optimal health outcomes and reach viral suppression targets. The assessment recommends strengthening of the capacity of lower health facilities-to provide ART to children and adolescents, use of a more effective ART regimen containing dolutegravir and finding innovative interventions to support VL suppression for the male child.
- Tivicay (dolutegravir) / ViiV Healthcare
Perspective of healthcare workers in Nigeria on the introduction of new pediatric antiretroviral drugs: experiences, enablers and barriers () - May 12, 2022 - Abstract #AIDS2022AIDS_1602;
Findings from the FGDs provided insight into the perspective of HCWs on the introduction of new pediatric ARVs. This will inform scale-up plans for transitioning clients to pDTG and increase preparedness for future ARV transitions.
- Tivicay (dolutegravir) / ViiV Healthcare
Perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda () - May 12, 2022 - Abstract #AIDS2022AIDS_1591;
Although weight gain is recognized as a side effect of DTG, it may be welcomed by some WLHIV. Healthcare professionals should actively talk about and monitor for weight gain and occurrence of associated comorbidities to facilitate timely interventions.
- Tivicay (dolutegravir) / ViiV Healthcare
Feasibility and efficacy of telephone-based psycho-educational intervention on psychological distress among people living with HIV in Ibadan, Nigeria () - May 12, 2022 - Abstract #AIDS2022AIDS_1584;
Ninety percent were on dolutegravir-based ART with an average of 90% adherence (based on self-report)... Telephone-based psychological intervention was feasible and demonstrated initial efficacy to reduce psychological distress in PLWH in Nigeria.
- Tivicay (dolutegravir) / ViiV Healthcare
Generating demand for pediatric dolutegravir 10 mg: early lessons from Afrocab's development of treatment literacy materials and subsequent collaboration with national governments () - May 12, 2022 - Abstract #AIDS2022AIDS_1484;
Community-friendly, accurate, and consistent treatment literacy materials are vital for generating demand for HIV products. Empowering communities to lead material development efforts and encouraging them to collaborate closely with MOHs should become the norm for pDTG's and future optimal HIV product introductions.
- Tivicay (dolutegravir) / ViiV Healthcare
Change in body weight after substituting efavirenz for dolutegravir in adults living with HIV in Johannesburg, South Africa () - May 12, 2022 - Abstract #AIDS2022AIDS_958;
PLWH on ART gained more weight after substituting EFV for DTG than did those remaining on EFV. Future studies with longer-term follow-up are needed to confirm these findings in larger cohorts and investigate the effects of cardiometabolic disease risk factors.
- Tivicay (dolutegravir) / ViiV Healthcare
Self-reported antiretroviral therapy use and detection of antiretrovirals: findings from sequential population surveys in Malawi () - May 12, 2022 - Abstract #AIDS2022AIDS_952;
The findings indicate consistency between self-reported ART use and ARV detection with evidence of high ART adherence. Unwillingness to disclose HIV+ status and ART use was rarely noted.
- Tivicay (dolutegravir) / ViiV Healthcare
Potential HIV-1 elite controllers in Malawian population and their impact on HIV epidemic control estimates () - May 12, 2022 - Abstract #AIDS2022AIDS_948;
However, their inclusion in epidemic control estimates may not affect accuracy of the results. Our study was limited in that ECs were defined based on single point VL testing.
- Tivicay (dolutegravir) / ViiV Healthcare
Adherence and resistance to ART among postpartum women with HIV in KwaZulu-Natal, South Africa () - May 12, 2022 - Abstract #AIDS2022AIDS_877;
Adherence to ART needs to be addressed to prevent failure of newer first line regimens, including Dolutegravir containing regimens, and second line regimens. Self-reported adherence tools may have limited benefit in assessing adherence to ART showing the need for early treatment support for all WWH.
- Tivicay (dolutegravir) / ViiV Healthcare
High levels of Acquired HIV Drug Resistance (ADR) among HIV positive Zambian adults with HIV treatment failure: results from the national ADR survey () - May 12, 2022 - Abstract #AIDS2022AIDS_856;
38.1% (95% CI: 33.4'43.0%) in ADR12 and 34.6% (95% CI: 27.4'42.5%) in ADR48 were receiving Dolutegravir (DTG)-based ART... High ADR to NNRTI and NRTI at early and late time points of ART was observed in Zambia.We recommend prompt switching to effective ART in those without VLS and continuous HIVDR surveillance for newer INSTI ARVs.
- Tivicay (dolutegravir) / ViiV Healthcare
Impact of Dolutegravir (DTG) on viral load suppression and HIV Drug Resistance (HIVDR) among Zambian children on ART: Results from the pediatric Acquired HIVDR (pADR) national survey () - May 12, 2022 - Abstract #AIDS2022AIDS_855;
To improve VLS and overall outcomes in CLHIV on ART, there is an urgent need to accelerate the transition to DTG-based ARV regimens. Programmatic gaps in the treatment cascade including routine HIVDR monitoring need to be strengthened.
- bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Minimal acquired resistance to dolutegravir and bictegravir in patients failing third-line ART in South Africa () - May 12, 2022 - Abstract #AIDS2022AIDS_852;
However, cross-resistance to dolutegravir and bictegravir remained limited, confirming the need to replace raltegravir with dolutegravir. Although only one dolutegravir-exposed patient presented with resistance to dolutegravir and bictegravir, three patients presented with resistance to raltegravir and cabotegravir.
- bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Combined effects of the K156N integrase polymorphism and 3'PPT resistance mutations against integrase inhibitors () - May 12, 2022 - Abstract #AIDS2022AIDS_845;
The structural changes imparted by K156N to integrase structure may facilitate the development of resistance. Further investigation is needed to evaluate the clinical significance of our work.
- Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD), Vitekta (elvitegravir) / Japan Tobacco, Gilead
Effects of integrase strand transfer inhibitors (INSTIs) on body mass index and blood pressure in children living with HIV () - May 12, 2022 - Abstract #AIDS2022AIDS_816;
Dolutegravir, raltegravir and elvitegravir were prescribed for 33 (29%), 43 (38%), and 37 (33%), respectively. INSTI-containing regimens do not appear to be associated with increases in BMI percentile or BP in CLWPH in Canada.
- Tivicay (dolutegravir) / ViiV Healthcare
Improving viral load suppression rate among paediatricpatientson anti-retroviral therapy in Central Province, Zambia () - May 12, 2022 - Abstract #AIDS2022AIDS_807;
While children may be managed at the health facility, client level factors are also key to attaining viral suppression. Therefore, MoH and all HIV treatment partners should work to identify and address both facility level and client level factors.
- Isentress (raltegravir) / Merck (MSD)
Uptake of raltegravir granules in newborns diagnosed with HIV in Zimbabwe during the COVID-19 pandemic () - May 12, 2022 - Abstract #AIDS2022AIDS_805;
Lower than expected birth testing uptake and RAL usage were observed, in large part due to inconsistent supply chain and trained human resources shortages during COVID-19. Addressing health systems gaps for supply chain, staffing (training, retention, mentorship, and supervision), and ability to track HIV-positive newborns is needed to improve birth testing services and outcomes for HIV-exposed infants, timely ART initiation, and follow-up on optimized regimens.
- Tivicay (dolutegravir) / ViiV Healthcare
Optimizing ART for CALHIV by shifting PI-based ART to dolutegravir-based ART maintained and achieved viral load suppression () - May 12, 2022 - Abstract #AIDS2022AIDS_801;
Shifting from PI-based to DTG-based ART was effective at maintaining and achieving VLS in CALHIV, and no loss of VLS was observed. These results support programmatic efforts to shift CALHIV from PI-based to DTG-based regimens, especially if unsuppressed on PI-based ART.
- Tivicay (dolutegravir) / ViiV Healthcare
A community-driven approach to pediatric Dolutegravir (pDTG) based regimen transition among children of key populations living with HIV in Nigeria () - May 12, 2022 - Abstract #AIDS2022AIDS_800;
This evidence demonstrates that a KP family-centered and community-driven ARV delivery mechanism is an effective approach to rapid transitioning to PDTG Based regimens for CLHIV of key population . There is need to compare this approach with other methods in further study.
- Tivicay (dolutegravir) / ViiV Healthcare
High rate of HIV virologic failure in children under the age of five in Tanzania () - May 12, 2022 - Abstract #AIDS2022AIDS_799;
Providers should be prepared to address comorbidities in these children, especially TB and malnutrition. Finally, advocacy for availability of pediatric drug formulations, especially dolutegravir, will likely benefit young children.
- Tivicay (dolutegravir) / ViiV Healthcare
The 'magic bullet' for HIV viral suppression? How fixed-dose combination Dolutegravir (DTG) antiretrovirals are improving viral suppression among children aged 10-14 years on antiretroviral therapy (ART) in Zambia () - May 12, 2022 - Abstract #AIDS2022AIDS_798;
Finally, advocacy for availability of pediatric drug formulations, especially dolutegravir, will likely benefit young children. Expanded access to DTG-containing regimens is an important intervention for increasing viral suppression rates in CLHIV for good individual health outcomes, and for fast-tracking achievement of HIV epidemic control.
- Tivicay (dolutegravir) / ViiV Healthcare
Associations between HIV/ART exposure during pregnancy and adverse maternal and infant outcomes in the MANGO cohort in western Kenya () - May 12, 2022 - Abstract #AIDS2022AIDS_793;
Transfer status, a likely indicator of women at increased risk of adverse pregnancy outcomes, should be accounted for when implementing pharmacovigilance programs at tertiary facilities. Pharmacovigilance programs need to continue monitoring adverse outcomes as new antiretrovirals become available in resource-limited settings.
- Tivicay (dolutegravir) / ViiV Healthcare
A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG) use during pregnancy: data from DOLOMITE-NEAT ID Network study () - May 12, 2022 - Abstract #AIDS2022AIDS_791;
While the numbers are too small to make definitive conclusions, no significant difference in frequency of birth defects was observed for first trimester exposures compared to 2 nd /3 rd trimester exposures with no neural tube defects in either. Most achieved viral suppression at delivery.
- Tivicay (dolutegravir) / ViiV Healthcare
Periconceptional dolutegravir use and risk of adverse pregnancy outcomes in Kenya () - May 12, 2022 - Abstract #AIDS2022AIDS_787;
We did not find a NTD signal or a difference in adverse pregnancy outcomes between DTG and EFV cohorts. These findings are consistent with other published studies and support current WHO guidelines to use DTG as a preferred first-line ARV drug in all populations.
- Tivicay (dolutegravir) / ViiV Healthcare
Targeted delivery of dolutegravir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach () - May 12, 2022 - Abstract #AIDS2022AIDS_771;
However, current cART including DTG does not eradicate HIV from these reservoirs in MLNs. Therefore, it is likely that higher levels of DTG are required for eradicating the virus from MLNs.
- Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
Efficacy of Tenofovir alafenamide versus tenofovir disoproxil fumarate among HIV positive Zambian adults switched from NNRTI to dolutegravir-containing ART: results from the VISEND clinical trial () - May 12, 2022 - Abstract #AIDS2022AIDS_768;
In addition, virologic outcomes for pregnant women receiving TAF based ART were comparable to those receiving TDF based therapy. There is therefore need to expand the use of TAF in HIV-1 infected individuals.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Safety and efficacy of switching to BIC/FTC/TAF plus DOR in HIV-infected patients with multiclass-resistant virus () - May 12, 2022 - Abstract #AIDS2022AIDS_757;
This study evaluated the safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF) plus dolutegravir (DTG), to BIC/FTC/TAF plus DOR in multiclass-resistant patients... Switching from RPV/FTC/TAF plus DTG to BIC/FTC/TAF plus DOR in HIV-infected males with multiclass-resistant virus was well tolerated and efficacious with an advantageous AE profile and no food restrictions.
- Tivicay (dolutegravir) / ViiV Healthcare
Low level of virologic failure and resistance in ART-experienced, integrase inhibitor-naïve participants receiving dolutegravir (DTG) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) combined regimens: 10-year follow-up in the SAILING Study () - May 12, 2022 - Abstract #AIDS2022AIDS_756;
Switching from RPV/FTC/TAF plus DTG to BIC/FTC/TAF plus DOR in HIV-infected males with multiclass-resistant virus was well tolerated and efficacious with an advantageous AE profile and no food restrictions. Although this analysis was on a selected small subgroup, the low rate of virologic failure, PDVF, and viral resistance observed through extended 10-year follow-up continuously support the higher resistance barrier of DTG, and that DTG+NRTIs regimen is durable and effective treatment for treatment-experienced patients harboring ART-resistant HIV-1.
- Tivicay (dolutegravir) / ViiV Healthcare
Comparison of virologic suppression rates among first- and second-line antiretroviral therapy patients at an urban clinic in Zimbabwe: a cohort study () - May 12, 2022 - Abstract #AIDS2022AIDS_752;
PLWH with history of VF are still less likely to achieve virologic suppression after switching to second-line ART. We recommend close monitoring and adherence support among this population after switching, particularly among young PLWH with history of VF, even in the DTG era.
- Vocabria (cabotegravir oral) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Cost-effective continuous flow synthesis of HIV second and third generation integrase inhibitor drugs: a step towards local API manufacturing in Africa () - May 12, 2022 - Abstract #AIDS2022AIDS_746;
To a great extent, efficient and cost-effective continuous flow procedure towards dolutegravir and cabotegravir was developed. The local API manufacture could be facilitated using this very efficient approach to the synthesis to effort an end of HIV epidemic.
- Advanced HIV infection in the US: immune response to ART initiation () - May 12, 2022 - Abstract #AIDS2022AIDS_745;
In the OPERA cohort, all ART-naïve, adults with advanced HIV (CD4200 cells/µL). No difference was observed in CD4:CD8 ratio changes over time across groups; CD4:CD8 ratio normalization was rare with all regimens.
- Tivicay (dolutegravir) / ViiV Healthcare
Association between Dolutegravir use and weight gain among adults in Tanzania () - May 12, 2022 - Abstract #AIDS2022AIDS_712;
DTG use was associated with weight gain in the study population and was more among those with lower immunity.Close monitoring is necessary to identify those who may need to be switched to other regimens due to excessive weight gain. It is also importance to adopt mechanisms for early HIV diagnosis before advanced immunocompromise.
- Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Weight changes and pregnancy outcomes among pregnant people living with HIV in use of integrase inhibitors initiated before or after conception: a cohort study () - May 12, 2022 - Abstract #AIDS2022AIDS_711;
In this cohort, PPLHIV who entered treatment during pregnancy with BMI '¤ 25 experienced significant WG using II. Such gain was not observed in participants who conceived using II or treatment-naïve PPLHIV with baseline BMI > 25.
- Tivicay (dolutegravir) / ViiV Healthcare
Perceptions of health, body size and nutritional risk factors for obesity among people with and without HIV in South Africa () - May 12, 2022 - Abstract #AIDS2022AIDS_704;
Recently, the South African HIV treatment program has begun to transition all patients to dolutegravir-based ART, despite evidence that this medication may promote weight gain... Both self-perception and SSB intake may offer entry points for future interventions to reduce obesity among PWH.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide vs. a dolutegravir-based regimen among a prospective longitudinal cohort of virologically suppressed adults living with HIV () - May 12, 2022 - Abstract #AIDS2022AIDS_703;
Of 956 enrolled, 673 switched to BIC/F/TAF, 148 switched to F/TAF plus DTG, 51 switched to DTG/ABC/3TC, 48 switched to DTG/RPV and 36 switched to DTG/3TC...Compared to switching from integrase strand transfer inhibitors (INSTIs), switching from efavirenz (EFV) was associated with significantly higher annualized weight gain post-switch (+3.11 kg/year, p<0.001), whereas switching from RPV was associated with significantly lower annualized weight gain post-switch (-2.17 kg/year, p=0.022)... In this real-world cohort, switching to a BIC vs. DBR were both associated with lower annualized weight gain post-switch that was not significantly different at Week 48; however, patients switching from EFV gained significantly more weight, while those switching from RPV gained significantly less weight post-switch compared to those switching from INSTIs.
- Incidence of cardiometabolic outcomes among people living with HIV initiated on INSTI versus non-INSTI antiretroviral therapies () - May 12, 2022 - Abstract #AIDS2022AIDS_700;
Among treatment-naïve PWH in the US, INSTI initiation was associated with greater risk of developing congestive heart failure, myocardial infarction, and lipid disorders during a short follow-up period. With increasing life expectancy among PWH, further research including additional clinical variables and using longer follow-up is warranted to examine the impact of INSTI-containing ART on long-term clinical outcomes.
- Tivicay (dolutegravir) / ViiV Healthcare
Where do we stand in the path towards cervical cancer elimination in Mozambique? () - May 12, 2022 - Abstract #AIDS2022AIDS_678;
Mozambique has the opportunity to eliminate cervical cancer. Increases in screening and treatment coverage rates are a result of successful coordination between government and stakeholders, but further improvement is needed.
- Pifeltro (doravirine) / Merck (MSD), Prezcobix (darunavir/cobicistat) / Gilead, J&J
Reversibility of neuropsychiatric adverse events after switching to darunavir/cobicistat or doravirine in men on INSTI based regimen () - May 12, 2022 - Abstract #AIDS2022AIDS_668;
NPAEs seem to be associated in patients on INSTI based regimen; these NPAEs improve after switching to DRV/c or DOR based regimen since the first 4 weeks. ISI and PHQ-9 are quick, easy, and self-reported questionnaires to test on each visit.
- Tivicay (dolutegravir) / ViiV Healthcare
Clinical and virologic outcomes of TB/HIV co-infected patients treated with dolutegravir-based HIV antiretroviral regimens: programmatic experience from Nigeria () - May 12, 2022 - Abstract #AIDS2022AIDS_627;
Use of DTG-based antiretroviral therapy with rifampicin based anti-TB drugs in TB/HIV patients has better TB treatment outcome than non-DTG based therapy. Effort should be geared towards transitioning all TB-HIV co-patients to DTG-Based ART except if contra-indicated.
- Tivicay (dolutegravir) / ViiV Healthcare
Safety and pharmacokinetic of daily isoniazid/rifapentine (1HP) in adults with HIV on standard dose of dolutegravir () - May 12, 2022 - Abstract #AIDS2022AIDS_625;
Although there were substantial reductions in DTG concentrations when co-administered with 1HP, C min levels were still above the protein-binding-adjusted IC 90 of 0.064 µg/mL and majority of them (>90%) remained virologically suppressed. Future large studies are warranted to confirm the findings.
- Daklinza (daclatasvir) / BMS, Tivicay (dolutegravir) / ViiV Healthcare
Quantifying the health and economic impact of voluntary licensing of HIV medicines in low- and middle-income countries: putting numbers on additional uptake, deaths averted, and money saved by MPP licences (Room 516/Channel 6) - May 12, 2022 - Abstract #AIDS2022AIDS_483;
Results for atazanavir (ATV), DTG (now also for paediatric use), lopinavir/ritonavir (LPV/r), and tenofovir disoproxil fumarate (TDF), together representing > 95% of MPP impact so far, are presented... Modelling the impact of MPP licences for HIV medicines offers visibility on the overall contribution to the global HIV response of the MPP model of public-health oriented voluntary licensing and a means to assess the investment (additional expenditure) that would be needed for the same level of optimal drug uptake without MPP licences: 22 billion USD in cumulative theoretical expenditures avoided by 2030.
- Tivicay (dolutegravir) / ViiV Healthcare
Survival in advanced AIDS patients treated with efavirenz or dolutegravir in Brazil: a multicenter, observational study (Room 517b/Channel 4) - May 12, 2022 - Abstract #AIDS2022AIDS_162;
Advanced AIDS patients treated with DTG had a higher proportion of viral suppression/survival rate/ immune restoration, less lipids changes, and lower discontinuation rates after 48 weeks than patients treated com EFV. DTG is confirmed as a preferential option to treat advanced AIDS patients.
- Tivicay (dolutegravir) / ViiV Healthcare
Dolutegravir versus efavirenz-400 as first-line ART in Cameroon: week 192 data of NAMSAL trial (Room 517b/Channel 4) - May 12, 2022 - Abstract #AIDS2022AIDS_161;
DTG-based and low dose EFV-based regimens has durable efficacy and safety for use in treatment-naïve patients with HIV-1. There was significantly more weight gain with the DTG-containing regimen.
- Tivicay (dolutegravir) / ViiV Healthcare
Efficacy and safety of dolutegravir plusemtricitabinevs combined antiretroviral therapy for the maintenance of viral suppression: 144-week results of the SIMPL'HIV trial (Room 517b/Channel 4) - May 12, 2022 - Abstract #AIDS2022AIDS_159;
DTG+FTC remains safe and non-inferior to standard care in the maintenance of viral suppression in adults with HIV-1 at 144 weeks. No new safety signals were observed and change weight was similar between groups.
- Tivicay (dolutegravir) / ViiV Healthcare
The fast and the continuous: dolutegravir-based antiretroviral therapy achieves impressive viral load suppression in CALHIV in the short- and long-term (Room 517b/Channel 4) - May 12, 2022 - Abstract #AIDS2022AIDS_19;
DTG rapidly achieved and consistently maintained VLS for years among CALHIV in real world settings. These findings support the widespread use of DTG in CALHIV.